About this event

BIX (BIOPLUS-INTERPHEX KOREA) — Detailed Research Description

BIOPLUS-INTERPHEX KOREA (BIX) is a bio-pharmaceutical exhibition and conference platform designed as an “all-round bio & pharma business platform.” The event is structured around the full bio-pharmaceutical value chain and combines exhibition, conference sessions, partnering, and open innovation to support business expansion through global networks. Based on the official event information, BIX 2026 is scheduled for October 28–30, 2026 at COEX, Seoul. It is hosted by KoreaBIO (Korea Biotechnology Industry Organization) and organized by RX Korea.

Event Snapshot (From Official Event Source)

• Event Title: BIOPLUS-INTERPHEX KOREA (BIX)
• Date: October 28 (Wed) – October 30 (Fri), 2026
• Venue: COEX Hall C (3F), The Platz (2F), and Conference Room (3&4F), Seoul
• Host: KoreaBIO (Korea Biotechnology Industry Organization)
• Organizer: RX Korea
• Theme (Official): World’s Most Tangible Bio-healthcare Convention
• Scale (Official expected): 10,000+ visitors / 300+ exhibitors with 600+ booths / 36 sessions with 120 speakers etc. (expected)
• Program Components (Official): Exhibition, Conference, Partnering, Open Innovation, Reception, Docent (etc.)

1️⃣ Who Attends (Buyers / Attendees)

BIX is not a single-industry-only meeting; it is built to bring decision makers across the bio-pharmaceutical value chain together. The official program description emphasizes “delivering domestic and international decision makers representing the entire value chain/full product development life cycle, from R&D to inspection & distribution.” That means the strongest “buyer-fit” attendance generally includes roles responsible for evaluating partners, technologies, services, and solutions across the bio-healthcare lifecycle.

Main attendee groups (buyer-like participants)

• Bio-pharma R&D & Translational teams: roles that evaluate discovery platforms, process development direction, and technology readiness.
• Clinical and translational decision makers: teams focused on how programs move through development and compliance steps.
• Manufacturing / process and CDMO-related decision makers: teams that assess manufacturing capability, scale-up readiness, and quality systems.
• Quality, compliance & inspection stakeholders: organizations and teams that need inspection/distribution readiness aligned with standards.
• Supply chain / inspection & distribution stakeholders: decision makers who evaluate logistics, distribution operations, and operational controls.
• Technology and solutions buyers: companies seeking exposure to the latest technologies and services in the sector through exhibition + conference content.
• Investors / bio-investor ecosystem participants: BIX highlights opportunities to present to bio-investors and corporate officials, indicating investor-adjacent attendance as well.
• Exhibitors and partner-seeking enterprises: organizations using partnering, open innovation, and one-on-one meetings to meet business counterparts.

In practical buyer-list terms, the best-fit attendee profiles are typically “decision influencers” and “evaluators” rather than only general visitors: procurement-only roles are less central in events framed around value-chain strategy, partnership matching, and technology evaluation. We focus our targeting on those who can qualify vendors, technologies, or partners aligned with bio-pharma development and commercialization needs.

2️⃣ Where the Show Is Happening + Attendee Geographic Origin

Location (Official): COEX, Seoul. The event footprint spans COEX Hall C (3F), The Platz (2F), and Conference Rooms (3&4F).

Attendee geographic origin (evidence-based framing): The official event description states the platform is designed to deliver “domestic and international decision makers.” Since the host is KoreaBIO and the event is hosted in Seoul, the strongest base is expected to be Korea-centric, with meaningful participation from international bio-pharma organizations, service providers, technology companies, and partners looking to connect into the Korean and broader Asian bio-healthcare ecosystem. We typically position BIX as a Korea + internationally connected audience rather than a purely domestic-only conference.

Best geographic targeting (how we approach it)

• Primary: Korea-based decision makers across bio-pharma, R&D, manufacturing, quality, and commercialization operations.
• Secondary: International organizations seeking partnerships, visibility, and solution evaluation in Korea (and the region).
• Strategic extension: Global value-chain players who want “full lifecycle” exposure (R&D → inspection & distribution).

3️⃣ Audience Reach (Local / National / Global)

BIX is best categorized as Global with strong domestic gravity. The official platform framing emphasizes a “full range of bio-pharmaceutical industry value chain” and explicitly mentions domestic and international decision makers. Additionally, BIX is part of an INTERPHEX Global Events series (INTERPHEX US, INTERPHEX Japan, API China). That global event ecosystem context usually increases international participation from bio-pharma and allied solution providers.

For reach planning, we treat BIX as: National (Korea) + international network building—especially valuable for vendors who sell to the bio-healthcare value chain.

4️⃣ Sample Buyer Company Names (BUYERS ONLY) + Websites

Below are example buyer-fit company targets that represent organizations commonly involved in bio-pharma development, manufacturing, compliance/inspection, and related bio-healthcare operations. We include them as starting points for research and outreach list building. Note: We have not verified each company’s exhibitor/visitor status from the provided source text. We recommend validating attendance/exhibitor alignment using the event exhibitor directory and attendee session topics.

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Samsung Biologics	https://www.samsungbiologics.com	VP / Head of External Manufacturing Partnerships; Director, Business Development	BIX value chain focus (R&D to inspection & distribution) aligns with CDMO partnership and capability evaluation.
2	Celltrion	https://www.celltrion.com	Director, Technology Transfer; Head of Quality Strategy	Bio-pharma lifecycle operations require strong inspection, compliance, and development-to-manufacturing integration.
3	SK Biopharmaceuticals	https://www.skbiopharma.com	Head of Process Development; Director, Quality & Compliance	High fit to evaluate process development, manufacturing solutions, and quality/inspection support.
4	Hanmi Pharmaceutical	https://www.hanmi.co.kr	Director, Clinical Operations; Head of Translational Development	Clinical/translational stakeholder presence is consistent with “full product development life cycle” framing.
5	Novartis	https://www.novartis.com	Global Head of Platform Partnerships; Director, External Innovation	Open innovation and partnering structures map well to global pharma seeking technology and collaboration.
6	Pfizer	https://www.pfizer.com	Director, Biopharma Partnerships; Head of External Collaboration	Conference + partnering formats match external partner discovery across bio-pharma lifecycle needs.
7	Roche	https://www.roche.com	VP, Biopharma Manufacturing Strategy; Head of Quality Systems	“Inspection & distribution” relevance strongly connects to quality systems and operations.
8	Merck (MSD)	https://www.merck.com	Director, CDMO/Partner Strategy; Head of Bio-operations Development	Value chain coverage plus technology trend focus makes partner and operational buyers a strong target.
9	Lonza	https://www.lonza.com	Business Development Director (Biologics); Strategic Partnerships Lead	Direct alignment with bio-manufacturing capabilities and lifecycle solutions evaluation.
10	WuXi AppTec	https://www.wuxiapptec.com	Director, Business Development (Biologics); Head of Partnership Ecosystem	R&D and development lifecycle services map well to partnering and conference sessions.
11	Catalent	https://www.catalent.com	Director, Development Services Partnerships; Quality Partnerships Lead	Inspection/distribution and development lifecycle themes are relevant to operational service buyers.
12	Charles River Laboratories	https://www.criver.com	Business Development Manager (Biopharma); Director, Discovery & Safety Services	Early-stage and development support typically intersects with R&D and value-chain decision making.
13	Thermo Fisher Scientific	https://www.thermofisher.com	Director, Strategic Accounts (Biopharma); Regional Industry Lead, Biopharma	Exhibition + conference sessions usually attract biopharma equipment/service buyers and technology evaluators.
14	Danaher (Cytiva / life sciences brands within)	https://www.danaher.com	Director, Bioprocess Sales; Head of Strategic Marketing for Bioprocess	Bioprocess and technology buyers are commonly present in full value-chain events.
15	GE HealthCare	https://www.gehealthcare.com	Director, Life Sciences Solutions Partnerships; Regional Sales Director, Bio	For bio-healthcare and inspection-adjacent workflows, solution buyers often evaluate technologies at such platforms.
16	Eurofins (Eurofins Scientific)	https://www.eurofins.com	Head of Quality & Compliance Services; Business Development Director (Bio/Pharma)	Quality, inspection, testing, and compliance services strongly match the event’s lifecycle emphasis.
17	SGS	https://www.sgs.com	Director, Pharma Inspection Services; Head of Life Sciences Quality Assurance	“Inspection & distribution” messaging aligns well with inspection, certification, and quality assurance buyers.
18	Intertek	https://www.intertek.com	Pharmaceutical Services Director; Head of Compliance & Inspection	Compliance/inspection stakeholders are a natural fit for BIX’s full lifecycle narrative.
19	AB InBev (as an example of large life-science adjacent buyers is NOT ideal)	https://www.abinbev.com
19	Pfizer CentreOne (reference brand within Pfizer ecosystem)	https://www.pfizer.com	Quality & Distribution Operations Lead; Director, External Manufacturing Oversight	Strong alignment with operational readiness and distribution/quality workflows under value-chain coverage.
20	Biotech Innovators / Korea regional biopharma developer (generic target)		Head of Business Development; Director, Alliance Management	We recommend selecting the exact buyer set based on your product category and which stage of the value chain it supports.

Top buyer-fit starting points (highest confidence categories): Samsung Biologics, Celltrion, SK Biopharmaceuticals, Lonza, WuXi AppTec, Thermo Fisher Scientific, Eurofins, SGS. These represent a strong mix across biomanufacturing, lifecycle services, quality/inspection, and enabling technologies.

5️⃣ Job Profiles, Industries & Event Type

Best job profiles to target (buyer decision roles)

• Partnership / alliance leadership: Director Business Development, Head of Strategic Partnerships, Alliance Management Director
• External innovation: Director Open Innovation, External Innovation Lead, Technology Partnerships Manager
• R&D and process decision roles: Head of Process Development, Director Technology Transfer
• Quality & inspection alignment: Head of Quality Systems, Director Quality Strategy, Pharma Inspection Services Director
• Manufacturing lifecycle roles: VP/Head of Biopharma Manufacturing Strategy, Manufacturing Operations Lead
• Inspection & distribution operations: Distribution Operations Director, Compliance & Distribution Lead
• Corporate and investor-facing ecosystem: Investor Relations Biotech Lead, Corporate Development Director (partner evaluation)
• Conference session buyers (technical evaluators): Technical Program Lead, Platform Evaluation Manager, Scientific Liaison (for vendor qualification)

Industries to map (from our industry taxonomy approach)

For BIX, we map buyer companies into several high-relevance industry buckets:

• Pharmaceuticals
• Biotechnology
• Medical Devices (when product touches diagnostics, instrumentation, or regulated devices adjacent to bio workflows)
• Research (when buyers focus on R&D and lab / discovery enabling platforms)
• Hospital & Health Care (only when the offering targets clinical infrastructure or healthcare delivery linked to bio programs)
• Events Services is not primary here; BIX buyer value is mainly technical + bio lifecycle decision makers.
• Information Technology & Services only if the product is regulatory-tech, quality systems software, lab informatics, or data platforms used in bio operations.

Event type classification

• Bio-pharmaceutical industry exhibition
• Conference + technical sessions (36 sessions / 120 speakers expected)
• Partnering and open innovation
• Networking and reception
• Lifecycle coverage across R&D to inspection & distribution

6️⃣ Estimated Attendance (Expected Total Footfall)

The official event scale states: 10,000+ visitors and 300+ exhibitors with 600+ booths. It also indicates 36 sessions with 120 speakers (expected).

What this means for buyer discovery: The visitor population includes students? (not stated in the provided source) and broader industry visitors. The highest value for our buyer-list approach is usually the subset of “decision makers” explicitly described in the event program information. Therefore, we structure outreach around value-chain decision roles and partnering/session participants, rather than trying to treat all visitors as procurement buyers.

7️⃣ Key Focus Areas & Buyer Engagement

BIX explicitly highlights several program and value propositions that shape buyer engagement: “keynote sessions, over 30 conferences, exhibition, partnering, open innovation and networking opportunities.” It also states the platform delivers decision makers representing the “entire value chain/full product development life cycle, from R&D to inspection & distribution.”

Key focus areas (inferred directly from official descriptions)

• Full bio-pharma value chain coverage (R&D → inspection & distribution)
• State-of-the-art technology trends presented by industry-wide experts
• Partner discovery through partnering platform (one-on-one meetings)
• Open innovation initiatives for collaboration
• Sponsor-facing visibility through customized promotion (per sponsorship program framing)
• Bio-investor and corporate official exposure via special opportunities to present
• On-site guided exhibition experience (docent tours / influencers guiding exhibition)

Best buyer engagement angles for outreach

• Lifecycle alignment message: We position the outreach to connect with buyers who care about the stage the product supports (development, manufacturing, inspection, distribution readiness).
• Partnering platform relevance: We highlight one-on-one meeting logic—evaluators and alliance managers are typically more responsive when we reference partnership outcomes.
• Technology-trend relevance: We anchor outreach to “state-of-the-art” and “latest technology & services” themes.
• Quality & compliance credibility: For inspection/distribution-related offerings, we emphasize quality systems, validation, and compliance outcomes (consistent with the event’s lifecycle emphasis).

8️⃣ Client-Product Fit: We Need Your Website to Recommend the Best Buyers

BIX buyer relevance changes significantly depending on what your product does within the bio-pharmaceutical lifecycle. The official event framing covers everything from R&D to inspection & distribution, so buyer selection differs for: enabling lab technologies, process development tools, manufacturing systems, quality/inspection services, compliance software, or distribution/operations solutions.

Please share your client product website (URL). After we review the website, we will:

• Map your product to the correct stage(s) of the value chain (R&D, development services, manufacturing support, inspection/quality, distribution/commercial operations).
• Select the best-fit buyer segments (job titles + industry types) for BIX.
• Provide a prioritized “top buyer list” with recommended job titles and outreach angles aligned to BIX’s partnering/open innovation structure.

While we wait for the client website: We can already recommend that buyers most likely to match are those in: partnerships/alliance management, process & technology transfer, quality systems, and inspection/compliance, because those roles most directly benefit from “value chain + full lifecycle” exposure.

9️⃣ Suggested Industry Targets for Research (Using Our Industry Taxonomy Approach)

Based on BIX’s official description (bio-pharmaceutical value chain, R&D, inspection & distribution, technology trends, partnering, open innovation), we recommend applying these industry filters when we build or refine buyer lists:

• Biotechnology
• Pharmaceuticals
• Research
• Medical Devices (selectively, if your offering is adjacent to diagnostics, regulated instrumentation, or clinical lab workflows)
• Information Technology & Services (selectively, if your offering is QMS/LIMS/regulatory tech/automation software used by bio teams)
• Hospital & Health Care (only if your offering targets clinical operations or bio-healthcare delivery systems)
• Professional Training & Coaching (only if your offering is regulated training, GMP training, or compliance education for bio operations)

Recommended Next Step

Send us your client website URL and a 2–3 sentence description of the product category (e.g., “bio-process automation,” “quality inspection services,” “regulatory compliance software,” “CDMO process development,” “lab instrumentation,” etc.). After we review it, we will produce: a prioritized buyer shortlist tailored to BIX 2026 with the best target job titles and the most relevant outreach angles for the event’s conference + partnering ecosystem.